Biological Availability Clinical Trial
Official title:
A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of a Probe CYP3A4 Inhibitor and Inducer on the Pharmacokinetics of BAY1841788 (ODM 201) in Healthy Male Volunteers
Verified date | July 2018 |
Source | Bayer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Evaluate the effect of a probe CYP3A4 inhibitor and inducer on the pharmacokinetics of BAY1841788 (ODM-201)
Status | Completed |
Enrollment | 15 |
Est. completion date | July 19, 2017 |
Est. primary completion date | May 4, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 45 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Healthy subject - as determined by the investigator or medically qualified designee based on medical evaluations including medical history, physical examination, laboratory tests and cardiac monitoring. - Gender: Male. - Age: 45 to 65 years (inclusive) at the screening visit. - Race: White. - Body mass index (BMI): =18.0 and =30 kg/m^2. - Agree to use condoms as an effective contraception barrier method and refrain from sperm donation during the whole study (starting after informed consent) and for 3 months after the end of treatment with ODM-201. In addition, participants must agree to utilize a second reliable method of contraception simultaneously. The second method which has to be used by a female partner of childbearing potential can be one of the following methods: diaphragm or cervical cap with spermicide or intra-uterine device or hormone-based contraception. - Results of alcohol tests are negative at screening and on Study Day -1. Exclusion Criteria: - Medical and surgical history - Existing relevant diseases of vital organs (e.g. liver diseases, heart diseases), central nervous system (for example seizures) or other organs (e.g. diabetes mellitus). Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal. - Febrile illness within 1 week before the first study drug administration. - A medical history of risk factors for Torsades de Pointes (e.g. family history of Long QT Syndrome) or other arrhythmias. - Known severe allergies, non-allergic drug reactions, or (multiple) drug allergies (excluding untreated, asymptomatic seasonal allergies like non-severe hay fever during the time of study conduct). - Known history of hypersensitivity (or known allergic reaction) to itraconazole, rifampicin or ODM-201. - Relevant hepatic disorders like cholestasis, disturbances of bilirubin metabolism, any progressive liver disease. - Relevant renal disorders like recurrent glomerulonephritis, renal injury, and renal insufficiency. However, a history of a single episode of uncomplicated nephrolithiasis will not prevent participation. - Subjects with porphyria. - Subjects with diagnosed malignancy within the past 5 years except for cured skin basal carcinoma. |
Country | Name | City | State |
---|---|---|---|
Germany | CRS Clinical Research Services Berlin GmbH | Berlin |
Lead Sponsor | Collaborator |
---|---|
Bayer | Orion Corporation, Orion Pharma |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of Darolutamide in Plasma After Single Dose Administration of Darolutamide | Area under the concentration versus time curve from time zero to 72 hours of Darolutamide after single dose administration in plasma were measured. | Pre dose to 72 hours post dose of darolutamide | |
Primary | Maximum Observed Concentration (Cmax) of Darolutamide in Plasma After Single Dose Administration of Darolutamide | Maximum observed concentration after single dose administration in plasma were measured. | Pre dose up to 72 hours post dose of darolutamide | |
Primary | Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of (S,R)-Darolutamide in Plasma After Single Dose Administration of Darolutamide | Area under the concentration versus time curve from time zero to 72 hours of (S,R)-Darolutamide in plasma after single dose administration of Darolutamide were measured. | Pre dose up to 72 hours post dose of darolutamide | |
Primary | Maximum Observed Concentration (Cmax) of (S,R)-Darolutamide in Plasma After Single Dose Administration of Darolutamide | Maximum observed concentration of (S,R)-darolutamide in plasma after single dose administration of darolutamide were measured. | Pre dose up to 72 hours post dose of darolutamide | |
Primary | Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of (S,S)-Darolutamide in Plasma After Single Dose Administration of Darolutamide | Area under the concentration versus time curve from time zero to 72 hours of (S,S)-darolutamide in plasma after single dose administration of darolutamide were measured. | Pre dose up to 72 hours post dose of darolutamide | |
Primary | Maximum Observed Concentration (Cmax) of (S,S)-Darolutamide in Plasma After Single Dose Administration of Darolutamide | Maximum observed concentration of (S,S)-darolutamide in plasma after single dose administration of darolutamide were measured. | Pre dose up to 72 hours post dose of darolutamide | |
Primary | Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of Keto-Darolutamide in Plasma After Single Dose Administration of Darolutamide | Area under the concentration versus time curve from time zero to 72 hours (AUC[0-72h]) of keto-Darolutamide in plasma after single dose administration of darolutamide were measured. | Pre dose up to 72 hours post dose of darolutamide | |
Primary | Maximum Observed Concentration (Cmax) of Keto-Darolutamide in Plasma After Single Dose Administration of Darolutamide | Maximum observed concentration of keto-darolutamide in plasma after single dose administration of darolutamide were measured. | Pre dose up to 72 hours post dose of darolutamide | |
Secondary | Number of Subjects With Study Drug-Related Treatment Emergent Adverse Events (TEAEs) | An adverse event (AE) was any untoward medical occurrence in subject who received study drug without regard to possibility of causal relationship. AEs that started or worsened after first administration of study medication up to 30 days after end of treatment with study medication were considered to be treatment-emergent (TE). AEs that occurred on study drug administration were termed as study drug related adverse events. | From start of study drug administration up to 30 days after last dose of study medication |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05544786 -
Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
|
Phase 1 | |
Completed |
NCT04744233 -
Bioavailability of Carotenoids From Orange Juice in a Cross-over Study in Healthy Subjects.
|
N/A | |
Completed |
NCT05561075 -
Oral Bioavailability of Pterostilbene Cocrystal Compared to Its Free Form (BIOPTERO)
|
N/A | |
Completed |
NCT03873909 -
Bioavailability of Carotenoids Present in Mamey Sapote (Pouteria Sapota (Jacq.) H. E. Moore & Stearn) Fruit
|
N/A | |
Completed |
NCT03353857 -
Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
|
Phase 1 | |
Completed |
NCT05121506 -
A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults
|
Phase 1 | |
Completed |
NCT01267201 -
A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form
|
Phase 1 | |
Completed |
NCT02538393 -
Relative Bioavailability of Sorafenib Tablet for Oral Suspension
|
Phase 1 | |
Completed |
NCT05116982 -
Effect of Three Silicon Based Food Supplements on the Urinary Excretion of Aluminum and Other Metals (SILIAL)
|
N/A | |
Completed |
NCT04207372 -
Protein Digestibility of Whey and Zein.
|
N/A | |
Completed |
NCT01853800 -
Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
|
Phase 1 | |
Completed |
NCT00714584 -
Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04876261 -
Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements
|
N/A | |
Completed |
NCT03886597 -
Nutritional Intervention With Table Olives in Healthy Volunteers
|
Phase 1/Phase 2 | |
Completed |
NCT06289140 -
Oral Bioavailability of a New Formulation of Pterostilbene Cocrystal in Comparison With Its Free Form (BIOPTERO2)
|
N/A | |
Completed |
NCT05439408 -
Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03951025 -
Study of the Bioavailability of a Food Supplement Rich in Melatonin Administered Sublingually and Orally (MELATONIN)
|
Phase 2 | |
Completed |
NCT03984916 -
Study of the Bioavailability of Three Hesperidin Extracts.
|
N/A | |
Completed |
NCT02966704 -
Stable Isotope Method to Assess Dietary Protein Quality
|
N/A | |
Completed |
NCT02847117 -
Bioavailability of the Microconstituents of Natural Chios Mastiha in Healthy Adults.
|
N/A |